| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200-1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | ILT5; ILT8; CD85b; ILT-8; LILRB3; LILRB6 |
| Entrez GeneID | 79168 |
| clone | 1B5B11 |
| WB Predicted band size | 52.4kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human LILRA6 (AA: 52-195) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于LILRA6抗体的3篇参考文献示例(内容为模拟生成，仅供参考)：
---
1. **文献名称**：*The role of LILRA6 in modulating monocyte inflammatory responses*
**作者**：Smith A, et al. (2019)
**摘要**：本研究揭示了LILRA6在单核细胞中的表达模式及其通过抑制TLR信号通路调节炎症反应的作用。通过开发特异性抗体，作者证实阻断LILRA6可增强促炎细胞因子分泌。
---
2. **文献名称**：*LILRA6 antibody as a potential biomarker in autoimmune diseases*
**作者**：Wang X, et al. (2021)
**摘要**：文章报道LILRA6抗体在系统性红斑狼疮(SLE)患者血清中显著升高，并通过体外实验证明该抗体可能通过干扰免疫复合物清除加剧疾病进展。
---
3. **文献名称**：*Structural characterization of LILRA6 and its interaction with HLA class I molecules*
**作者**：Tanaka K, et al. (2017)
**摘要**：利用X射线晶体学解析LILRA6胞外结构域，发现其与HLA-I分子的结合模式，并开发了功能性抗体用于阻断该互作，为靶向治疗提供依据。
---
**注**：以上文献为示例，实际引用请通过PubMed/Google Scholar检索真实研究。
The leukocyte immunoglobulin-like receptor subfamily A member 6 (LILRA6), also known as ILT8 or CD85g, is a cell surface receptor belonging to the LILR family, which regulates immune responses by interacting with MHC class I molecules. LILRA6 is primarily expressed on myeloid cells, including monocytes, macrophages, and dendritic cells, and exists in both membrane-bound and soluble forms due to alternative splicing. Unlike other activating LILRs, LILRA6 lacks a canonical signaling motif but may modulate immune activation through interactions with signaling adaptor proteins or by competing with inhibitory receptors for ligand binding. Its exact ligands and downstream pathways remain poorly characterized, though it is hypothesized to recognize conserved regions of MHC class I or pathogen-associated molecules.
Research on LILRA6 antibodies focuses on their utility in detecting receptor expression in immune cells and dissecting its functional roles. Dysregulation of LILRA6 has been implicated in autoimmune diseases, chronic inflammation, and cancer, where altered receptor expression may influence immune evasion or hyperactivation. Antibodies targeting LILRA6 are essential tools for immunohistochemistry, flow cytometry, and functional studies to explore its involvement in disease pathogenesis. Additionally, therapeutic antibodies or antagonists are being investigated for modulating LILRA6 activity in conditions like rheumatoid arthritis or malignancies. Despite progress, further studies are needed to clarify its ligand specificity, signaling mechanisms, and therapeutic potential.
×
